Comment on Media Report
-
Olivier Martinez Seeks Increased Child Support from Halle Berry Following Custody Change
-
Police Investigate Bedford Parent for Hallway Incident After Playoff Loss
-
Joe Biden Makes Surprise Appearance at Trinity College Dublin for Hunter's Medal
-
Regal Cinemas Launches 4DX Screenings for 'Heated Rivalry' Amid Immersive Theater Trend
-
Bank of Korea Governor Shin Hyun-song Appointed First Asian Chair of BIS Payment Committee
-
Texas Car Buyers: Legal Remedies When a Defective Vehicle Isn't a 'Lemon'
-
Northern California Jewish Sports Hall of Fame Announces 2026 Inductees
-
Phil Spencer on Housing Market Fairness: How Buyers and Sellers Navigate Falling Prices
-
Readers Debate GTA 6 Spin-offs, Server Strain, and Warner Bros. Decline in Games Inbox
Comment on Media Report
Evotec SE (Frankfurt Stock Exchange:EVT) (SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480 (NASDAQ:EVO) With respect to a media report, Evotec SE ("Company") declares that it has received, without prior contact, a non-binding expression of interest from the listed US biotechnology company Halozyme Therapeutics Inc. regarding a takeover offer addressed to the shareholders of the Company with an offer price of EUR 11.00 per share. The Company will carefully analyze this expression of interest, decide on next steps, and inform the capital market in accordance with the legal requirements.
Contact: Volker Braun, EVP Head of Global Investor Relations & ESG, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49 (0) 151 1940 5058 (m), [email protected]
SOURCE: Evotec SE
P.Smith--AT
